Childhood depression

Article written and reviewed by Dr Luca Moretti

The term childhood depression describes depressive disorders that occur in children, particularly before adolescence. It is not an autonomous diagnosis in DSM-5-TR or ICD-11: a child may meet the criteria for major depressive disorder, persistent depressive disorder or other depressive categories, but the assessment must interpret symptoms, emotional language, behavior and functional impairment in light of the developmental stage.

This distinction is clinically important because prepubertal depression is not simply a miniature version of adult depression. Children may have difficulty describing sadness, guilt or hopelessness, and the change may emerge mainly in play, school performance, peer relationships, behavior at home or through somatic complaints. DSM-5-TR explicitly recognizes that, in children and adolescents, irritable mood may replace depressed mood in the criterion for a major depressive episode.

Depressive disorders are less common in childhood than in adolescence. A meta analysis of studies conducted between 2004 and 2019 in children younger than 13 years estimated an overall prevalence of depressive disorders of about 1.07% and of major depressive disorder of about 0.71%. In the same study, the marked sex difference that becomes evident after puberty did not emerge during preadolescence. These values depend on the diagnostic method, the population studied and the distinction between a clinically defined disorder and depressive symptoms alone.

Early onset deserves particular attention because it may interfere with educational attainment, development of social skills and the formation of self esteem. In addition, a depressive episode in childhood identifies a group with greater vulnerability to subsequent depressive recurrences and other psychiatric disorders. This does not mean that childhood depression inevitably progresses to a chronic illness: the individual course is heterogeneous and depends on severity, duration, comorbidity, familial vulnerability, persistence of stressors and access to effective care.

Depression may be underrecognized because irritability, oppositional behavior, reduced school engagement or physical complaints are sometimes interpreted exclusively as educational or personality problems. The historical concept of “masked depression”, however, should not be used to automatically attribute depressive significance to nonspecific behaviors: diagnosis requires documentation of a syndromic picture, a compatible duration and clinically significant impairment.

Every assessment must also include suicide risk. Thoughts of death, self harm and suicide attempts are less frequent than in adolescence but can also occur in children, and young age is not a reason to omit direct questions, phrased in understandable language, about the wish to die, the intention to harm oneself and access to dangerous means.

Etiology, Pathogenesis and Pathophysiology

There is no single specific cause of childhood depression. Available evidence supports a multifactorial model in which genetic predisposition, neurobiological development, temperament, relational experiences, adverse events, chronic stress and coexisting medical or psychiatric conditions modify the probability of developing a depressive episode. No single factor is necessary or sufficient, and the presence of family difficulties does not, in itself, demonstrate a causal relationship.

A family history of depression and other mood disorders is one of the most reproducible risk factors. Family and genetic studies indicate a hereditary component, but the architecture is polygenic and the effects of individual variants are small. In children, genetic predisposition is expressed within a developing organism and interacts with the environment, so there is no genetic test that can be used to diagnose or individually predict depression.

Childhood adversities, including maltreatment, abuse, neglect, domestic violence, bullying, loss of significant figures and persistent family stress, are associated with increased risk. These exposures may influence emotion regulation, interpersonal expectations and biological stress systems, but the relationship is probabilistic: most children exposed to a single adverse event do not necessarily develop depression, and a depressive disorder may also occur without an identifiable trauma.

Family functioning is relevant primarily as a context of risk, protection and treatment. Depression or other psychiatric disorders in parents, high conflict, limited emotional availability and instability may increase risk through intertwined genetic and environmental mechanisms. It is nevertheless incorrect to turn these associations into a model that blames parents: causality is complex and bidirectional, and a depressed child may in turn alter family dynamics.

Anxiety disorders, ADHD, neurodevelopmental disorders, learning difficulties and chronic illnesses may increase vulnerability or complicate the clinical picture. In particular, the combination of persistent school difficulties, social rejection and low self esteem may help maintain symptoms. Comorbidity should not, however, be interpreted as a simple “cause” of depression: disorders often share risk factors and influence one another over time.

At the neurobiological level, the literature identifies average alterations in circuits involved in reward, emotion regulation, threat processing and cognitive control. Neuroimaging and neurophysiological studies show group level differences, but findings are heterogeneous and influenced by age, pubertal maturation, severity and comorbidity. No structural or functional alteration is sufficiently specific to be used as a diagnostic biomarker in an individual child.

The traditional hypothesis of a simple “serotonin deficiency” is inadequate. Serotonin, norepinephrine and dopamine participate in mood regulation, but pathophysiology involves broader networks, synaptic plasticity, glutamatergic systems, neurotrophic factors and emotional learning processes. The fact that some antidepressants act on monoaminergic transmission does not demonstrate that depression results from a single neurochemical deficiency.

Stress response systems, including the hypothalamic pituitary adrenal axis, have also been studied in early onset depression. Prolonged exposure to stress may alter neuroendocrine regulation and interact with sleep, immunity and brain plasticity. Studies, however, do not identify a necessary or specific endocrine profile: cortisol and other markers are not diagnostic tests for childhood depression.

Sleep has a bidirectional relationship with depressive symptoms. Insomnia, difficulty falling asleep, awakenings and, less commonly, hypersomnia may be part of the episode, while persistent sleep disturbances may increase emotional vulnerability and interfere with learning and behavior. Before attributing these manifestations to depression, sleep habits, respiratory disorders, neurological syndromes and environmental conditions should be considered.

During childhood, pathophysiology cannot be separated from neurodevelopment. The abilities to identify emotions, use cognitive strategies, understand the permanence of death and anticipate future consequences change rapidly with age. The same depressive mechanism may therefore produce different manifestations in a six year old child and an eleven year old child, making a developmental interpretation of symptoms essential.

In summary, functional impairment emerges when biological and psychological vulnerabilities, stress and contextual factors persistently alter the systems that regulate pleasure, motivation, sleep, attention and social behavior. In children, this may disrupt daily cycles of positive reinforcement: reduced participation in play and relationships decreases rewarding experiences, promoting further withdrawal, loss of perceived efficacy and worsening mood.

No blood, genetic, endocrine, inflammatory or neuroimaging biomarker is currently validated for clinical diagnosis. Pathophysiology is therefore useful for understanding the disorder and developing therapies, but diagnosis remains based on history, observation, clinical criteria and functioning.

Clinical Manifestations

The clinical assessment should begin by reconstructing the change from usual functioning. In children, a parent or teacher is often the first to report that the child plays less, avoids friends, has become irritable, cries frequently, struggles to get ready for school or has lost interest in activities previously sought spontaneously.

The history should include an interview with parents or caregivers and, using age appropriate methods, a direct interview with the child. Reports may differ: internal symptoms, such as sadness, guilt or thoughts of death, may be better known by the child, whereas adults and teachers more accurately observe changes in behavior, performance and relationships. This discrepancy does not invalidate the assessment but is a feature of developmental psychiatry.

Depressed mood may be expressed as sadness, crying, loneliness or negative statements about oneself. In other cases, persistent irritability predominates. It is essential to distinguish episodic irritability associated with a global change in functioning from chronic irritability present for years, which may point toward other disorders and requires longitudinal reconstruction.

Anhedonia may present as loss of interest in games, sports, hobbies, parties, friendships or family activities. A child who continues an activity because parents encourage it may still no longer experience the usual pleasure. Reduced spontaneous play is particularly informative in younger children, in whom introspective language is still limited.

Cognitive symptoms may emerge as difficulty concentrating, slowness with tasks, indecision, apparent inattention and declining school performance. They should not automatically be interpreted as ADHD: in ADHD, attentional problems are typically more persistent and trans situational, whereas in depression they may represent a change temporally associated with other affective symptoms.

Sleep disturbances include difficulty falling asleep, nocturnal awakenings, early morning awakening or increased sleep. Fear of sleeping alone and a request for greater proximity to parents may occur, but these phenomena are nonspecific and should be interpreted within the overall clinical context. Appetite and weight trajectory also require attention, considering that in children the DSM criterion may manifest as failure to achieve expected weight gain rather than obvious weight loss.

Fatigue may translate into reduced participation, complaints of tiredness, slowness and requests for help with tasks previously performed independently. Psychomotor slowing or agitation, when present, must be observable and not limited to subjective perception. In very active children, depression does not exclude periods of movement or play, so judgment must be based on the overall picture and persistence of the change.

Self devaluation and guilt take developmentally compatible forms: the child may call themselves “bad” or “incapable”, believe that no one wants to play with them, or assume disproportionate responsibility for family problems. These cognitions should be differentiated from transient reactions to reprimands or failures and assessed for intensity, pervasiveness and interference.

Somatic complaints, such as headache or abdominal pain, may accompany depression and anxiety but are not specific. The presence of physical symptoms does not justify concluding that they are “psychosomatic” without appropriate medical evaluation. A depressed child may simultaneously have an organic disease, and a psychiatric diagnosis must not become a residual explanation for symptoms that have not yet been clarified.

Social withdrawal, irritability, angry outbursts and oppositional behavior may be more visible than sadness. However, isolated aggressive or oppositional behaviors do not constitute depressive criteria. It is necessary to determine whether they occur together with loss of pleasure, neurovegetative changes, negative cognitions or other features of the episode.

Depression may impair school and social development. Absences, school refusal, loss of participation, declining results and peer conflict may be consequences or perpetuating factors. The school history should include any learning difficulties, bullying, classroom changes and educational support already available.

Anxiety disorders are common and may precede or accompany depression. ADHD, autism spectrum disorders, trauma, behavioral disorders and obsessive compulsive symptoms should also be investigated. The presence of comorbidity changes functioning and the treatment plan and may explain why the clinical picture does not respond to an intervention directed only at mood.

The assessment should directly explore thoughts of death and suicide. Questions should be phrased simply and progressively, distinguishing curiosity about death, a wish to disappear, thoughts of self harm, intent, planning and preparatory behaviors. Caregivers should be asked about access to medications, weapons or other dangerous means, and any previous episodes of self harm should be assessed.

The mental status examination observes appearance, contact, activity level, speech, affect, ability to play and interaction. In children, observing the relationship with the caregiver may add information, but by itself it cannot establish the cause of the disorder. Drawing and play may facilitate clinical communication, but they are not projective diagnostic tests capable of confirming depression.

Investigations and Diagnosis

There are no autonomous diagnostic criteria for a condition called “childhood depression”. According to DSM-5-TR and ICD-11, diagnosis must identify the specific depressive disorder present and interpret its expression in relation to age. For major depressive disorder, the diagnostic core is the major depressive episode, with the possibility in children of considering irritable mood instead of depressed mood.

DSM-5-TR criteria applicable to major depressive disorder in children

• During the same period of at least two weeks, at least five symptoms must be present, representing a change from previous functioning; at least one must be depressed or irritable mood or markedly diminished interest or pleasure.
• Depressed mood for most of the day and on most days; in children the criterion may be met by persistent irritable mood.
• Markedly diminished interest or pleasure in all or almost all activities for most of the day and on most days, which in children may present as reduced play and participation in usual activities.
• Significant unintentional weight loss or gain, or decreased or increased appetite; during development, failure to achieve expected weight gain must also be considered.
• Insomnia or hypersomnia nearly every day.
• Psychomotor agitation or retardation nearly every day, observable by others and not limited to a subjective feeling.
• Fatigue or loss of energy nearly every day.
• Feelings of worthlessness or excessive or inappropriate guilt nearly every day, not limited to self reproach about being ill.
• Diminished ability to think or concentrate, or indecisiveness nearly every day, reported by the child or observed by others.
• Recurrent thoughts of death, recurrent suicidal ideation, a suicide attempt or suicidal planning.
• The symptoms as a whole must cause clinically significant distress or impairment in social, school, family or other important areas of functioning.
• The episode must not be attributable to the physiological effects of a substance or another medical condition.
• To diagnose major depressive disorder, the presentation must not be better explained by schizophrenia spectrum disorders or other psychotic disorders, and there must be no history of a manic or hypomanic episode.

The first diagnostic phase is a multi-informant assessment. The clinician separately gathers information from the child and caregivers and, when useful and possible, from the school. Onset, duration, daily pattern, loss of functioning, previous episodes, stressors, illnesses, medications, family history and recent changes in the home or school environment should be defined.

The interview with the child should use language compatible with linguistic and cognitive abilities and allow time for a private conversation when age and maturity permit. The clinician should explain the limits of confidentiality in understandable terms, especially when safety risks emerge. Assessment cannot depend exclusively on the parents’ perception or solely on the child’s self report.

Structured or semistructured diagnostic interviews and pediatric scales can increase the systematic collection of symptoms. Instruments such as the Children’s Depression Inventory can support quantification, but no questionnaire is pathognomonic and no score replaces clinical diagnosis. An elevated result always requires verification of duration, impairment and differential diagnosis.

Suicide risk assessment is an integral part of the evaluation and should not be postponed while awaiting a definitive diagnosis. Ideation with intent, a plan, a recent attempt, inability of caregivers to ensure safety, psychotic symptoms, severe agitation, catatonia or refusal of food and fluids require urgent specialist assessment and determination of the safest care setting.

A central differential diagnosis is disruptive mood dysregulation disorder, characterized by persistent irritability and severe temper outbursts according to specific age and duration requirements. Episodic irritability in depression should not be confused with chronic dysregulation; similarly, irritability does not demonstrate bipolar disorder.

Bipolar disorder should be considered when there are distinct episodes of elevated or markedly irritable mood associated with a pathological increase in energy or activity and the other symptoms of mania or hypomania. A family history of bipolar disorder and activation with antidepressants may increase clinical vigilance, but they do not replace the criteria for a manic or hypomanic episode.

ADHD, anxiety disorders, oppositional defiant disorder, autism spectrum disorders, learning disorders and trauma related disorders may produce or accompany apparently depressive difficulties. The distinction relies especially on chronology: a recent deterioration superimposed on a stable neurodevelopmental condition may indicate comorbid depression.

Bereavement and other stressful events do not exclude a major depressive episode. Proportionate, fluctuating reactions to a loss should be distinguished from a pervasive depressive picture, and adjustment disorder should be evaluated when its criteria are met. It is incorrect to diagnose depression simply because a traumatic event is present, or to exclude it simply because an event occurred.

Medical investigations are targeted, not a fixed panel. History and physical examination may indicate the need for a complete blood count, thyroid function tests, metabolic assessments or other tests when symptoms, medications, growth or physical signs suggest an organic condition. Neuroimaging, EEG and extensive endocrine testing are not routine investigations for depression without specific clinical indications.

Sleep, nutrition, growth, puberty when appropriate, chronic pain, epilepsy and other illnesses that may contribute to symptoms should also be assessed. Medications or substances are less frequently involved than in adolescents, but the history should nevertheless include prescribed therapies and accidental or intentional access to substances.

The final diagnostic formulation should specify the disorder, severity, duration, any psychotic or mixed features, comorbidity, functioning and risk. It should also distinguish predisposing, precipitating, perpetuating and protective factors, because these elements guide treatment more than a generic label of childhood depression.

Treatment and Prognosis

Treatment should be designed according to age, developmental level, severity, risk, comorbidity and family context. In childhood, caregiver involvement is not an optional addition but is often necessary to ensure adherence, modify treatable environmental factors, support routines and monitor safety. This does not imply that the family is the cause of the disorder.

In mild forms, psychosocial interventions, psychoeducation, support for routines and close clinical monitoring may be appropriate. Persistent symptoms, functional deterioration or increasing risk require progression to structured treatments. Simply advising the child to “distract themselves” or “do more activities” does not constitute adequate therapy.

For children aged 5 to 11 years with moderate or severe depression, NICE lists developmentally adapted psychological options including family based interpersonal psychotherapy, family therapy, psychodynamic psychotherapy and individual cognitive behavioral therapy. Choice depends on maturity, clinical profile, communication, comorbidity, preferences and availability of competent treatments.

Cognitive behavioral therapy uses age adapted techniques to increase rewarding activities, recognize emotions, develop problem solving and modify dysfunctional interpretations. In younger children, the work is more concrete and behavioral and frequently involves the parent; with increasing maturity, greater work on automatic thoughts and cognitive strategies becomes possible.

Family therapies may be particularly useful when conflict, communication, caregiver stress or difficulty supporting routines contribute to persistence of the disorder. Bullying, school difficulties, learning disorders, insomnia and other modifiable conditions should be addressed in parallel. School intervention should be proportionate and agreed upon, avoiding both unrealistic expectations and prolonged withdrawal that promotes further isolation.

Pharmacological evidence is more limited in prepubertal children than in adolescents. NICE guidelines recommend, after multidisciplinary review, considering fluoxetine cautiously in children aged 5 to 11 years with moderate to severe depression that has not responded to a specific psychotherapy after 4 to 6 sessions, emphasizing that efficacy in this age group is less well established.

In the European Union, fluoxetine is authorized for children and adolescents from 8 years of age with a moderate to severe major depressive episode that has not responded to psychotherapy after 4 to 6 sessions, in association with psychological treatment. Below this age, use falls outside the authorized indication and requires an even more rigorous specialist assessment of the benefit risk balance.

Any antidepressant in a child requires appropriate informed consent, monitoring of response, adverse effects and the possible emergence or increase of suicidal ideation and suicidal behavior, especially during the initial phases and after dose changes. The presence of this warning does not mean that severe depression should be left untreated, but it requires specialist prescribing and structured monitoring.

Before pharmacotherapy, bipolar disorder, comorbidity, adherence to psychotherapy and psychosocial factors should be reassessed. If marked activation, reduced need for sleep, grandiosity or other symptoms suggestive of mania appear, the clinical picture should be reviewed promptly. It is not appropriate to automatically increase the dose by attributing every deterioration to depression.

Tricyclic antidepressants are not first line treatments for pediatric depression and have problems related to efficacy, anticholinergic effects and cardiotoxicity. Use of other antidepressants or augmentation strategies requires specialist expertise and an individual rationale, because pediatric evidence cannot be automatically extrapolated from adults.

Presentations with psychotic depression, catatonia, severe malnutrition, high suicide risk or failure to respond to multiple interventions require high intensity child and adolescent neuropsychiatric care. Electroconvulsive therapy and other somatic therapies have exceptional indications in pediatric age and are considered only in severe, selected and resistant cases, in centers with specific expertise.

Monitoring should include not only symptoms but also functional recovery: return to play, school attendance, relationships, sleep, autonomy and the ability to experience pleasure. Incomplete clinical remission and residual symptoms increase the risk of relapse and require continuation of treatment and follow up.

Prognosis is heterogeneous. Many children improve with appropriate interventions, but early onset is associated with a greater risk of depressive recurrence and subsequent psychosocial difficulties. Comorbidity, prolonged episodes, severe impairment, residual symptoms, suicidality and persistent stress are associated with a less favorable course at the group level.

Relapse prevention includes early recognition of signs of worsening, a safety plan, continuity of care and collaboration among family, health services and school. The goal is not merely to eliminate sadness but to protect the child’s developmental trajectory.

Complications

The most serious complication is suicidal behavior. Although suicide mortality is much rarer in children than in adolescents, thoughts of death, preparations and attempts can occur. Assessment should therefore be repeated over time and intensified in the presence of worsening, agitation, hopelessness, access to lethal means or previous self harming behavior.

Depression may interfere with learning through reduced concentration, energy and motivation, absences and lower participation. Prolonged decline at school can in turn reduce self efficacy and increase stress and conflict, creating a cycle that maintains symptoms.

Withdrawal from play and peers may impair acquisition of social skills and promote isolation. Loss of positive opportunities is not only a consequence but may become a perpetuating factor because it reduces experiences of success, belonging and reward.

Family conflicts may increase when irritability, apparent oppositional behavior and difficulties with routines are interpreted as deliberate disobedience. Psychoeducation also helps prevent punitive escalation and distinguish symptoms from normal educational responsibilities, without removing age appropriate limits and rules.

A depressive episode may be associated with anxiety disorders, ADHD or other conditions that increase disability and make remission more difficult. Persistence of symptoms despite apparently adequate therapy should therefore prompt investigation of untreated comorbidity and environmental factors, rather than only a change in medication.

Chronic sleep disturbances, reduced activity and changes in eating may worsen physical wellbeing and daily functioning. In severe presentations, weight loss, dehydration or severe self neglect may occur, requiring medical assessment and potentially changing the care setting.

Depressive symptoms may become persistent or recur during adolescence. The risk of recurrence is particularly relevant after severe or multiple episodes and in the presence of residual symptoms. Remission should therefore not automatically coincide with discontinuation of follow up.

In some patients, particularly those with a family history or suggestive features, the subsequent course may reveal bipolar disorder. Childhood depression does not necessarily “become” bipolar disorder, but longitudinal history may over time clarify a diagnosis that could not yet be defined during the first depressive episode.

Emotional pain may promote avoidance behaviors and, as adolescence approaches, increase vulnerability to self harm or substance use. These complications are much more characteristic of later ages, but the presence of early signs requires prompt intervention.

Long term effects are not inevitable. Accurate diagnosis, timely treatment, complete remission and developmental support can reduce persistence of disability. The central point is to recognize that childhood depression is a treatable condition but may be relevant across the entire life course.

Bibliography
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishing; 2022.
2. World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. World Health Organization; 2024.
3. Walter HJ et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. J Am Acad Child Adolesc Psychiatry. 62(5), 2023: 479-502.
4. National Institute for Health and Care Excellence. Depression in children and young people: identification and management. NICE guideline NG134. National Institute for Health and Care Excellence; 2019, updated 2025.
5. Spoelma MJ et al. Estimated Prevalence of Depressive Disorders in Children From 2004 to 2019: A Systematic Review and Meta-Analysis. JAMA Pediatr. 177(10), 2023: 1017-1027.
6. Thapar A et al. Depression in young people. Lancet. 400(10352), 2022: 617-631.
7. Singh MK et al. Genetics, epigenetics, and neurobiology of childhood-onset depression: an umbrella review. Mol Psychiatry. 29(3), 2024: 553-565.
8. Zhou X et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 7(7), 2020: 581-601.
9. Oud M et al. Effectiveness of CBT for children and adolescents with depression: A systematic review and meta-regression analysis. Eur Psychiatry. 57, 2019: 33-45.
10. Cipriani A et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 388(10047), 2016: 881-890.
11. March J et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study randomized controlled trial. JAMA. 292(7), 2004: 807-820.
12. European Medicines Agency. Prozac and associated names: referral information and conditions for use in children and adolescents. European Medicines Agency; 2006.
13. Viswanathan M et al. Screening for Depression and Suicide Risk in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 328(15), 2022: 1543-1556.
14. Clayborne ZM et al. Systematic Review and Meta-Analysis: Adolescent Depression and Long-Term Psychosocial Outcomes. J Am Acad Child Adolesc Psychiatry. 58(1), 2019: 72-79.